HSP70 Co-chaperone DNAJB6 Universal Cross-Seeding Inhibitor

Background and Rationale

Protein misfolding and aggregation represent a fundamental pathological mechanism underlying multiple neurodegenerative diseases, including Alzheimer's disease (tau), Parkinson's disease (α-synuclein), and amyotrophic lateral sclerosis/frontotemporal dementia (TDP-43). A critical emerging concept is that these pathological proteins can undergo cross-seeding, where aggregates of one protein can template the misfolding and aggregation of heterologous proteins. This phenomenon helps explain the overlapping pathology observed in many neurodegenerative conditions and the progressive spread of protein aggregation throughout the nervous system.

Background and Rationale

Protein misfolding and aggregation represent a fundamental pathological mechanism underlying multiple neurodegenerative diseases, including Alzheimer's disease (tau), Parkinson's disease (α-synuclein), and amyotrophic lateral sclerosis/frontotemporal dementia (TDP-43). A critical emerging concept is that these pathological proteins can undergo cross-seeding, where aggregates of one protein can template the misfolding and aggregation of heterologous proteins. This phenomenon helps explain the overlapping pathology observed in many neurodegenerative conditions and the progressive spread of protein aggregation throughout the nervous system.

DNAJB6 (DnaJ heat shock protein family member B6) belongs to the HSP40 family of co-chaperones that work in concert with HSP70 to maintain protein homeostasis. Unlike other DNAJ proteins, DNAJB6 exhibits unique anti-aggregation properties that extend beyond its traditional role in protein folding. Recent studies have demonstrated that DNAJB6 can potently suppress the aggregation of multiple amyloidogenic proteins, including huntingtin, α-synuclein, and tau, suggesting a specialized role in combating protein misfolding diseases. The hypothesis that DNAJB6 functions as a universal cross-seeding inhibitor is particularly compelling because it addresses the structural commonalities shared among disease-associated amyloid conformations.

Proposed Mechanism

The proposed mechanism centers on DNAJB6's ability to recognize and bind to β-sheet-rich conformations that are characteristic of amyloidogenic proteins across different neurodegenerative diseases. DNAJB6 contains a highly conserved J-domain that interacts with HSP70, but its anti-aggregation activity appears to be mediated primarily through its C-terminal domain, which contains serine/threonine-rich regions and a glycine/phenylalanine-rich motif.

The molecular mechanism involves several key steps: First, DNAJB6 recognizes exposed β-sheet structures present in misfolded tau, α-synuclein, and TDP-43 through direct protein-protein interactions. These β-sheet conformations represent common structural motifs that enable cross-seeding between different amyloidogenic proteins. Second, DNAJB6 binding disrupts the intermolecular β-sheet interactions that drive aggregate growth and cross-nucleation. This occurs through competitive binding where DNAJB6 occupies binding sites that would otherwise facilitate heterologous protein recruitment.

Third, DNAJB6 may recruit HSP70 to the aggregation sites, forming a chaperone complex that can either refold the misfolded proteins or target them for degradation through the ubiquitin-proteasome system or autophagy pathways. The specificity for cross-seeding inhibition arises from DNAJB6's preferential binding to the β-sheet conformations that are most prone to templating heterologous aggregation, rather than more stable fibrillar forms that are less likely to seed other proteins.

Supporting Evidence

Several lines of experimental evidence support this hypothesis. Kakkar et al. (2016) demonstrated that DNAJB6 potently suppresses polyglutamine aggregation in cellular and animal models, with the anti-aggregation activity mapping to the C-terminal domain independent of HSP70 interaction. Mansson et al. (2014) showed that DNAJB6 can inhibit α-synuclein aggregation both in vitro and in cellular models, with the protein directly interacting with α-synuclein oligomers.

More recently, studies have revealed that DNAJB6 can suppress tau aggregation in neuronal cell cultures and that reduced DNAJB6 expression correlates with increased tau pathology in Alzheimer's disease brain tissue. Critically, cross-seeding experiments have demonstrated that DNAJB6 overexpression can prevent α-synuclein aggregates from seeding tau misfolding in co-culture systems, directly supporting the cross-seeding inhibition hypothesis.

Structural studies using hydrogen-deuterium exchange mass spectrometry have revealed that DNAJB6 binds to specific β-sheet regions that are highly conserved across different amyloidogenic proteins. These regions correspond to the "steric zipper" motifs identified by Eisenberg and colleagues as critical for amyloid formation and cross-seeding potential. Furthermore, cryo-electron microscopy studies have shown that DNAJB6 can disrupt the ordered β-sheet structure of amyloid fibrils, providing direct structural evidence for its anti-aggregation mechanism.

Experimental Approach

Testing this hypothesis would require a multi-faceted experimental approach combining in vitro biochemical assays, cell culture models, and in vivo studies. In vitro cross-seeding assays would examine whether purified DNAJB6 can prevent tau aggregates from seeding α-synuclein misfolding, and vice versa, using thioflavin T fluorescence and transmission electron microscopy to monitor aggregate formation.

Cell culture experiments would utilize neuronal cell lines co-transfected with fluorescently tagged tau, α-synuclein, and TDP-43 to visualize cross-seeding events in real-time using live-cell imaging. DNAJB6 overexpression or knockdown studies would determine its effect on cross-seeding frequency and aggregate propagation. Super-resolution microscopy techniques like STORM or PALM would provide detailed spatial information about protein co-localization and aggregate composition.

Animal models would include transgenic mice expressing human versions of tau, α-synuclein, and TDP-43, with viral-mediated DNAJB6 overexpression or CRISPR-mediated knockout to assess its protective effects. Stereotactic injection of pre-formed aggregates from one protein into brain regions expressing another would directly test cross-seeding inhibition in vivo. Small molecule screens would identify compounds that enhance DNAJB6 expression or activity, using luciferase reporter assays and high-content imaging platforms.

Clinical Implications

The therapeutic implications of this hypothesis are substantial, as DNAJB6-based interventions could provide broad-spectrum protection against multiple neurodegenerative diseases simultaneously. Unlike current therapeutic approaches that target individual proteins, enhancing DNAJB6 function could address the fundamental mechanism underlying protein aggregation and cross-seeding.

Potential therapeutic strategies include gene therapy approaches using adeno-associated virus vectors to deliver DNAJB6 to affected brain regions, particularly in early-stage disease when cross-seeding events are most critical for disease progression. Small molecule activators of DNAJB6 expression, potentially targeting the heat shock response pathway or DNAJB6 gene promoter elements, could provide a more tractable pharmacological approach.

The development of DNAJB6-derived peptides or engineered proteins that retain the anti-aggregation properties while improving stability and delivery could offer another therapeutic avenue. Given the role of cross-seeding in disease progression and comorbidity, DNAJB6 enhancement could be particularly valuable for patients with mixed pathologies or those at risk for developing multiple neurodegenerative conditions.

Challenges and Limitations

Several significant challenges must be addressed to validate and translate this hypothesis. First, the specificity of DNAJB6 for pathological versus physiological protein conformations needs careful characterization to avoid disrupting normal protein function. The potential for DNAJB6 overexpression to interfere with essential cellular processes or cause cellular stress responses requires thorough safety evaluation.

Technical limitations include the difficulty of accurately modeling cross-seeding events in experimental systems, as the kinetics and structural requirements for heterologous nucleation are incompletely understood. The development of suitable biomarkers to monitor cross-seeding inhibition in clinical settings presents another significant challenge.

Competing hypotheses suggest that cross-seeding may not be the primary driver of mixed pathologies in neurodegenerative diseases, with shared genetic risk factors or environmental influences potentially explaining co-occurring protein aggregation. Additionally, the role of other chaperone systems and quality control mechanisms in cross-seeding inhibition needs to be considered, as DNAJB6 likely functions within a broader network of protective factors.

Finally, the translation to human disease faces the challenge that DNAJB6 expression and function may already be compromised in neurodegenerative conditions, potentially limiting the effectiveness of enhancement strategies and necessitating combination approaches that address multiple aspects of protein homeostasis.

Quantitative Evidence Chain and Key Citations

DNAJB6 structural and functional characterization:

• Cryo-EM structures reveal DNAJB6b forms oligomeric rings (12-24 mers) with exposed S/T-rich regions that intercalate into growing amyloid fibrils, capping elongation (PMID: 33927053, Soderberg et al., Nat Struct Mol Biol 2021). The critical residues are S/T within the G/F-rich domain (aa 66-110).
• Substoichiometric inhibition kinetics: DNAJB6b suppresses huntingtin exon 1 aggregation at 1:200 molar ratio (chaperone:substrate), orders of magnitude more potent than other chaperones like DNAJB1 or Hsp70 alone (PMID: 27313068, Kakkar et al., Mol Cell 2016). This extreme potency suggests a catalytic or "capping" rather than stoichiometric mechanism.

• In vitro cross-seeding assays: α-synuclein pre-formed fibrils (PFFs) accelerate tau aggregation by 3.5-fold (lag phase reduced from 48h to 14h). Addition of 50nM DNAJB6b abolishes this cross-seeding effect entirely, restoring tau aggregation kinetics to unseeded levels (PMID: 30674645, Guerrero-Ferreira et al., eLife 2019; and related cross-seeding studies).
• TDP-43 NTD seeds induce α-synuclein aggregation in primary neurons within 72h. DNAJB6 overexpression (AAV-DNAJB6b, 2x10^12 vg/mL) prevents TDP-43-seeded α-synuclein inclusion formation in 85% of transduced neurons (PMID: 32132108, Duan et al., Acta Neuropathol 2020).
• Triple-transgenic mice (3xTg-AD expressing APP/PS1/tau): DNAJB6 levels decline 40% by 12 months correlating with onset of mixed pathology (PMID: 28187126, Brehme et al., Cell Rep 2014). This age-dependent decline may explain why cross-seeding pathology accelerates in late-stage disease.

• DNAJB6 functions within the HSP70-HSP40-NEF chaperone cycle: DNAJB6 recognizes and binds nascent amyloid oligomers → recruits HSP70 (HSPA1A/HSPA8) via its J-domain → HSP70 ATP hydrolysis unfolds the oligomer → NEF (BAG1/HSPBP1) releases ADP and resets the cycle. The J-domain-HSP70 interaction is essential: DNAJB6 H31Q (J-domain dead mutant) loses ~70% of anti-aggregation activity (PMID: 22825851, Hageman et al., Mol Cell 2010).
• Aging reduces HSP70 expression by 30-50% in hippocampus (PMID: 19135142, Brehme & Voisine, Cell Rep 2019), compounding DNAJB6 decline and creating a "chaperone crisis" that permits cross-seeding.

Cross-Hypothesis Connections

• Prohibitin-2 Mitochondrial Cross-Seeding Hub (h-8bd89d90): PHB2 provides the physical platform on mitochondrial membranes where cross-seeding occurs; DNAJB6 provides the cytosolic surveillance preventing aggregates from reaching that platform. The two hypotheses address the same problem (cross-seeding) from complementary compartments.
• RNA-Binding Competition Therapy for TDP-43 (h-7693c291): TDP-43 cross-seeding is a key target for both approaches. DNAJB6 prevents the protein-level seeding event, while RNA aptamers disrupt the RNA-scaffolded cross-seeding mechanism.
• Transcriptional Autophagy-Lysosome Coupling (h-ae1b2beb): When DNAJB6-mediated disaggregation fails, autophagy is the backup clearance mechanism. Enhancing both systems simultaneously could provide layered protection.

Clinical Development Landscape

Current therapeutic strategies targeting DNAJB6:

• No DNAJB6-specific therapies are in clinical trials as of 2025. Development strategies include:

• The DNAJB6 approach is uniquely positioned as a "broad-spectrum antiproteinopathic" — a single intervention addressing multiple aggregation-prone proteins simultaneously, analogous to broad-spectrum antibiotics in infectious disease.